Johnson & Johnson scored a critical victory on Wednesday after a jury rendered a defense verdict in the first bellwether trial over the blood thinner Xarelto.
The drug has become a poster child for tort reformers who object to rampant advertising by plaintiffs attorneys in cases involving pharmaceuticals and medical devices. Johnson & Johnson subsidiary Janssen Pharmaceuticals Inc. and Bayer brought in powerhouse litigator Beth Wilkinson of Washington, D.C.’s Wilkinson Walsh + Eskovitz to lead the defense team at trial, which took place in New Orleans.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
